{
    "nctId": "NCT00404495",
    "officialTitle": "Phase 2 Single-Arm, Open Label Study Of Irinotecan In Combination With Temozolomide In Children With Recurrent Or Refractory Medulloblastoma And In Children With Newly Diagnosed High-Grade Glioma.",
    "inclusionCriteria": "* Cohort 1: Recurrent or refractory medulloblastoma in which current standard treatment approaches have failed; biopsy is not required for recurrent disease.\n* Cohort 2: Newly-diagnosed high-grade glioma (World Health Organization \\[WHO\\] grade 3 or 4)\n* Life expectancy \u2265 3 months\n* Must have minimum age of 6 Months\n* Must have maximum age of 18 Years",
    "exclusionCriteria": "* Diagnosis of brainstem glioma\n* Concurrent administration of any other anti-tumor therapy\n* Pre-existing uncontrolled diarrhea"
}